RHABDOMYOSARCOMA

This early-stage study is testing whether genetically modified immune cells can fight solid tumors in children and young adults. Researchers collect patients' own immune cells, modify them to better recognize and attack cancer cells, then infuse them back into the body. The study…

This early-stage study is testing a new type of personalized cell therapy for children and young adults whose rhabdomyosarcoma (a muscle cancer) has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better tar…

This early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific marker called GPC3. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, and then inf…

This early-stage study is testing a new, flavored, oral version of a chemotherapy drug called irinotecan (named Orotecan®) in children and young adults whose solid tumors have come back. The main goals are to find a safe and effective dose and to see how the body processes the dr…

This study is testing a new, unapproved pill called silmitasertib, given alongside standard chemotherapy drugs. It aims to find a safe and effective dose for children and young adults under 30 whose solid tumors (like neuroblastoma or sarcoma) have come back or stopped responding…

This early-stage study aims to find a safe and effective dose of a targeted radiation drug for children and teenagers with specific cancers that have come back or stopped responding to standard treatments. The therapy delivers radiation directly to cancer cells. Researchers will …

This study is testing the safety of a new type of stem cell transplant for children whose cancers have come back or are very hard to treat. Doctors use a half-matched family donor and a special process to remove certain immune cells from the transplant, aiming to reduce complicat…

This is a first-in-human study testing a new type of personalized cell therapy for children and young adults (up to age 21) whose solid tumors have come back or haven't responded to standard treatments. Doctors will collect a patient's own immune cells (T cells), genetically modi…

This early-stage study is testing the safety of a two-part treatment for advanced sarcomas that have stopped responding to standard therapies. Doctors take a patient's own immune cells, genetically modify them to recognize and attack cancer cells, and then infuse them back. These…

This is a first-in-human safety study for a new, two-part cell therapy for children and young adults whose cancers have come back or haven't responded to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target the cancer, a…

This study is testing a new combination of an immunotherapy drug (atezolizumab) with three chemotherapy drugs for children and young adults whose solid tumors have returned or not responded to prior treatment. The main goals are to first check if the combination is safe and then …

This study is testing a new type of stem cell transplant for children and young adults whose solid tumors have returned or not responded to standard treatments. Doctors are using a donor's stem cells that have been specially processed to remove certain immune cells, then combinin…

This study is testing a new drug called PEEL-224 combined with two existing cancer drugs to see if it can help control aggressive sarcomas that have returned or stopped responding to standard treatments. It will involve about 63 adolescents and young adults (ages 12-49) with spec…

This study aims to discover new genes that cause cancer to run in families, especially those affecting children. Researchers will collect health information, blood, and sometimes leftover tumor samples from families where multiple members have had cancer. The goal is to build a l…